CD34 and glioblastoma: A recent study from our laboratory demonstrated that Vatalanib treatment increased the number of CD68+ myeloid cells as well as the CD133+, CD34+, and Tie2+ endothelial cell signatures in a novel chimeric mouse model of GBM.